 |
 |
| |
|
Hydroxychloroquine 100mg, 200mg |
|
|
| |
 |
| |
Rheumatoid arthritis, juvenile rheumatoid arthritis
Discoid and systemic lupus erythematosus
Light sensitive diseases
Malaria and malaria prophylaxis |
|
|
| |
 |
| |
Rheumatoid arthritis : Initially 400mg daily. The
dose can be reduced to 200mg when no further
improvement is evident. The maintenance dose should
be increased to 400mg daily if the response lessens.
Malaria : To treat an acute attack it is usual to
give 800mg initially followed by 400mg in six to
eight hours, and then 400mg on each of two
successive days. A single dose of 800mg has been
used to eradicate Plasmodium falciparum infection
and to terminate an acute attack by Plasmodium vivax.
Malaria prophylaxis : 6mg/kg once a week (equivalent
to 400mg weekly in most cases). Prophylaxis should
be begin one week before arrival in a malarious area
and continue for four to eight weeks after leaving
the area. The dose may need to be doubled in highly
malarious areas. |
|
|
| |
 |
| |
Ocular reactions
A. Ciliary body : Disturbance of accommodation with
symptoms of blurred vision. This reaction is dose
related and reversible with cessation of therapy.
B. Cornea : Transient edema, punctuate to lineal
opacities, decreased corneal sensitivity. The
corneal changes, with or without accompanying
symptoms are fairly common, but reversible. Corneal
deposits may appear as early as three weeks
following initiation of therapy. |
|
|
| |
 |
|
|
|
acute myocardial infarction, Cardiogenic shock and
severe hypotension |
|
|
| |
 |
| |
|
When
prolonged therapy with any antimalarial compound
is contemplated, initial and periodic
opthalmologic examinations should be performed.
If there is any indication of abnormality in the
visual acuity, visual field, or any visual
symptoms which are not fully explainable by
difficulties of accommodation or corneal
opacities, the drug should be discontinued and
the patient observed for possible progression. |
|
|
